Duaklir Pressair FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 6, 2020.
FDA Approved: Yes (First approved March 29, 2019)
Brand name: Duaklir Pressair
Generic name: aclidinium bromide and formoterol fumarate
Dosage form: Inhalation Powder
Company: Circassia Pharmaceuticals plc
Treatment for: COPD
Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.
Development timeline for Duaklir Pressair
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.